A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

This is an early-phase study testing a new drug called JNJ-87562761 in people with multiple myeloma — a cancer of plasma cells in the bone marrow — whose disease has come back or stopped responding to prior treatments. **You may be eligible if...** - You have been diagnosed with multiple myeloma that has relapsed (come back) or is refractory (no longer responding to treatment) - Your disease is still measurable through blood, urine, or protein tests - You have already been treated with at least three types of prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 therapy - You have good performance status (able to carry out most daily activities) - Your kidneys are functioning adequately **You may NOT be eligible if...** - You have not received the required prior therapies - You have significant kidney impairment - You do not meet performance status requirements Talk to your doctor to see if this trial is right for you.